Striving for
Seizure Control
Without the Side Effects

our science

NeuroPro Therapeutics is a clinical-stage pharmaceutical company actively developing novel compounds to treat neurologic diseases, including epilepsy.

about us
patient design element for biotech website

for patients

Clinical trails planned in 2024.

Contact your provider to learn about combining your current epilepsy treatment with a new antiepileptic drug candidate.

patients
stethoscope design element for biotech website

for providers

Redefining epilepsy treatment. Improving lives.

Learn more about enrolling your epilepsy patients in our Phase 2 clinical trial.
providers

Our Lead Antiepileptic Drug Candidate

30% of epilepsy population/ unmet medical need. Proof of efficacy with similar results to bumetanide and furosemide (NKCC antagonists) in two pharmacology models.

  • NPT 2042 plasma exposures observed in all species, including humans
  • No negative safety signals observed with  NPT 2042 in animals or humans to date
NeuroPro Therapeutics Logo

NeuroPro Therapeutics is a clinical-stage pharmaceutical company actively developing proprietary compounds to treat neurologic diseases, including epilepsy.

contact us
  • ©2023 NeuroPro Therapeutics. All rights reserved.
Privacy